Reviewing Aeterna Zentaris Inc. (AEZS)’s and BioLineRx Ltd. (NASDAQ:BLRX)’s results – Stocks Beat

As Biotechnology companies, Aeterna Zentaris Inc. (NASDAQ:AEZS) and BioLineRx Ltd. (NASDAQ:BLRX) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Table 1 demonstrates Aeterna Zentaris Inc. and BioLineRx Ltd.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Aeterna Zentaris Inc. and BioLineRx Ltd.s return on equity, net margins and return on assets.

Insider and Institutional Ownership

The shares of both Aeterna Zentaris Inc. and BioLineRx Ltd. are owned by institutional investors at 21.4% and 27.13% respectively. About 0.6% of Aeterna Zentaris Inc.s share are owned by insiders. Insiders Comparatively, owned 3.46% of BioLineRx Ltd. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Aeterna Zentaris Inc.s stock price has smaller decline than BioLineRx Ltd.

Summary

On 4 of the 7 factors Aeterna Zentaris Inc. beats BioLineRx Ltd.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:

Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat